Iradimed Co (IRMD)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Iradimed Co.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 90.90 $ — 70% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
9 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 16.3% passed
- More than 10% revenue growth is expected for the coming year 10.6% passed
- Share count grows by less than 3% a year 0.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 34.9% failed
- Gross margin at 40% or higher and without meaningful erosion 76.8% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 51 m net cash passed
- Operating cash flow covers the profits of the last three years 5 m passed
- Return on capital at 15% or higher, or up versus two years ago 26.5% passed
- Insiders hold at least 10% or are net buyers 35.2% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 29.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 2
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.09 | 2.09 – 2.09 | 91 | 8.3% | 1 |
| 12/31/2027 | 2.41 | 2.39 – 2.42 | 101 | 15.1% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.40 | 13.00 | 19 | 11.10 | 26.50 | 6 | 3 |
| 2025: Q1 | 0.37 | 12.60 | 20 | 10.90 | 24.00 | 4 | 1 |
| 2025: Q2 | 0.45 | 17.20 | 20 | 13.80 | 28.30 | 8 | 5 |
| 2025: Q3 | 0.43 | 9.80 | 21 | 15.70 | 26.30 | 7 | 6 |
| 2025: Q4 | 0.50 | 24.30 | 23 | 17.00 | 28.40 | 6 | 5 |
| 2026: Q1 | 0.45 | 23.70 | 22 | 12.60 | 26.50 | 8 | 8 |
| 2026: Q2 | 0.41 | -8.90 | 21 | 0.50 | 25.40 | 6 | 6 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 33 | 11 | 7 | 0.60 | 9 | 32 | 37 |
| 2017 | 23 | 1 | 1 | 0.04 | 3 | 33 | 39 |
| 2018 | 30 | 6 | 6 | 0.52 | 7 | 42 | 48 |
| 2019 | 39 | 9 | 10 | 0.78 | 10 | 56 | 67 |
| 2020 | 32 | -1 | 1 | 0.11 | 6 | 61 | 71 |
| 2021 | 42 | 10 | 9 | 0.74 | 11 | 72 | 83 |
| 2022 | 53 | 16 | 13 | 1.02 | 10 | 74 | 86 |
| 2023 | 66 | 20 | 17 | 1.35 | 13 | 71 | 92 |
| 2024 | 73 | 22 | 19 | 1.50 | 26 | 87 | 98 |
| 2025 | 84 | 26 | 22 | 1.75 | 25 | 95 | 109 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
IRADIMED CORPORATION entwickelt, fertigt, vermarktet und vertreibt MRT-kompatible intravenöse Infusionspumpensysteme sowie MRT-kompatible Patientenvitalwert-Überwachungssysteme und zugehöriges Zubehör. Das Unternehmen bietet MRidium 3870 und 3860+ MRT-kompatible IV-Infus…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 166 |
| Headquarters | Orlando, FL |
| Address | 12705 Ingenuity Drive, 32826 Orlando, United States |
| Phone | 407 677-8022 |
| Website | iradimed.com |
| IPO Date | 16. Jul 2014 |
| ISIN | US46266A1097 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Roger E. Susi | Founder, Chairman, CEO & President | 1953 |
| John F. Glenn | CFO & Corporate Secretary | 1962 |
| Jeff Chiprin | Chief Commercial Officer | 1966 |
| Randy Waddell | Vice President of Worldwide Sales & Marketing | – |
| Chris Williamson | Executive Vice President of Continuous Improvement & Information Technology | – |
| Matt Garner | Controller | – |
| Lynn Neuhardt | Vice President of Research & Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 21. Apr 2026 | Roger E Susi | CEO | Sell | 2,500 | 90.94 | 227,350 |
| 20. Apr 2026 | Roger E Susi | CEO | Sell | 5,000 | 93.36 | 466,800 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.